Asia-Pacific Clinical Trials Market by Phase (Phase I, Phase II, Phase III), By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indications (Blood Disorders, Cancer, Circulatory, CNS, Congenital, CVS, Dermatology, Infections, Mental Disorders, Gastrointestinal) and By Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Asia-Pacific Clinical Trials Market by Phase (Phase I, Phase II, Phase III), By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indications (Blood Disorders, Cancer, Circulatory, CNS, Congenital, CVS, Dermatology, Infections, Mental Disorders, Gastrointestinal) and By Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 1655 | Pages: 135 | December 2016 | Region: Asia Pacific


The Asia-Pacific Clinical Trials market has been estimated at USD 3.25 Billion in 2016 and is projected to reach USD 4.97 Billion by 2021, at a CAGR of 8.9% during the forecast period from 2016 to 2021. Clinical Trials is a part of clinical research that follows a regulated protocol. Clinical Trials are primarily performed to get data on safety and efficacy of the new developed drug. Clinical Trials data is mandatory for further approval of the drug and to bring it into the market. They allow the drug to be tested for safety by different ethnic population. Due to the higher medical needs and increasing disease prevalence, developing countries are becoming a hub for Clinical Trials implementation.

The market for Clinical Trials is mainly driven due to advancement in technology and increasing demand of innovative solutions in healthcare, the cost competitiveness factor where the cost involved in performing a Clinical Trials in emerging nations is very less compared to Western nations and lenient regulatory matters. But, the market growth will be constrained due to emerging shortage of clinical resources such as lack of naïve disease population, well trained labor, and sound medical infrastructure which are delaying the process to initiate trials.

Asia-Pacific market for Clinical Trials is segmented based on Phase, design and indication. By Phase, the market is further sub-segmented into Phase I, Phase II, phase III. By design, the market is further sub-segmented into Interventional trials, Observational trials, Expanded Access trials. By indication, the market is further sub-segmented into Autoimmune, Blood disorders, Cancer, Circulatory, CNS, Congenital, CVS, Dermatology, Ear, Gastrointestinal, Genitourinary, Infections, Mental disorders, Metabolic, Musculoskeletal, Nose, Ophthalmology. Cancer and CNS are the largest market share contributors to the market. Segments like Gastrointestinal, Circulatory, Dermatology and Mental Disorders are moving with high CAGR due to their increasing occurrence.

Geographically, Asia-Pacific market for Clinical Trials is segmented into China, India, Japan, South Korea and Australia.  The Clinical Trials market in the Asia-Pacific region is projected to grow at the highest CAGR, which is greatly due to initiatives from the government and contributions from academic laboratories, which helped augment growth. Due to large population in this region, it helps in faster enrollment of the patients, and retention of the participants in the trials on the higher side; thereby helping the companies to conduct the trials on the timely basis.

Chiltern, Omnicare, PPD, Parexel, Kendle, Quintles, ICON Plc, and Charles River, are the major players of Asia-Pacific Clinical Trials market.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                             4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Phases                          

                                5.1.1 Introduction           

                                5.1.2 Phase I      

                                5.1.3 Phase II    

                                5.1.4 Phase III   

                                5.1.5  Y-o-Y Growth Analysis, By Phases                

                                5.1.6  Market Attractiveness Analysis, By Phases              

                                5.1.7  Market Share Analysis, By Phases                

                5.2 Design                          

                                5.2.1 Introduction           

                                5.2.2 Interventional trials             

                                5.2.3 Observational trials             

                                5.2.4 Expanded Access trials       

                                5.2.5  Y-o-Y Growth Analysis, By Design 

                                5.2.6  Market Attractiveness Analysis, By Design               

                                5.2.7  Market Share Analysis, By Design

                5.3 Indications                  

                                5.3.1 Introduction           

                                5.3.2 Autoimmune         

                                5.3.3 Blood disorders     

                                5.3.4 Cancer      

                                5.3.5 Circulatory               

                                5.3.6 CNS            

                                5.3.7 Congenital               

                                5.3.8 CVS            

                                5.3.9 Dermatology          

                                5.3.10 Ear            

                                5.3.11 Gastrointestinal  

                                5.3.12 Genitourinary      

                                5.3.13 Infections              

                                5.3.14 Mental disorders

                                5.3.15 Metabolic              

                                5.3.16 Musculoskeletal 

                                5.3.17 Nose       

                                5.3.18 Ophthalmology   

                                5.3.19  Y-o-Y Growth Analysis, By Indications      

                                5.3.20  Market Attractiveness Analysis, By Indications    

                                5.3.21  Market Share Analysis, By Indications      

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Phase

                                                6.1.3.3 By Design

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Phase

                                                6.1.4.3 By Design

                                                6.1.4.4 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Phase

                                                6.1.5.3 By Design

                                                6.1.5.4 By Indication

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Chiltern                        

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Omnicare                    

                8.3 PPD                

                8.4 Parexel                         

                8.5 Kendle                          

                8.6 Quintles                       

                8.7 ICON Plc                       

                8.8 Charles River                              

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Clinical Trial Market By Phase, From 2016-2021 ( USD Billion )
  2. Asia-Pacific Phase I Market By Region, From 2016-2021 ( USD Billion )
  3. Asia-Pacific Phase II Market By Region, From 2016-2021 ( USD Billion )
  4. Asia-Pacific Phase III Market By Region, From 2016-2021 ( USD Billion )
  5. Asia-Pacific Clinical Trial Market By Design, From 2016-2021 ( USD Billion )
  6. Asia-Pacific Interventional trials Market By Region, From 2016-2021 ( USD Billion )
  7. Asia-Pacific Observational trials Market By Region, From 2016-2021 ( USD Billion )
  8. Asia-Pacific Expanded Access trials Market By Region, From 2016-2021 ( USD Billion )
  9. Asia-Pacific Clinical Trial Market By Indications, From 2016-2021 ( USD Billion )
  10. Asia-Pacific Autoimmune Market By Region, From 2016-2021 ( USD Billion )
  11. Asia-Pacific Blood disorders Market By Region, From 2016-2021 ( USD Billion )
  12. Asia-Pacific Cancer Market By Region, From 2016-2021 ( USD Billion )
  13. Asia-Pacific Circulatory Market By Region, From 2016-2021 ( USD Billion )
  14. Asia-Pacific CNS Market By Region, From 2016-2021 ( USD Billion )
  15. Asia-Pacific Congenital Market By Region, From 2016-2021 ( USD Billion )
  16. Asia-Pacific CVS Market By Region, From 2016-2021 ( USD Billion )
  17. Asia-Pacific Dermatology Market By Region, From 2016-2021 ( USD Billion )
  18. Asia-Pacific Ear Market By Region, From 2016-2021 ( USD Billion )
  19. Asia-Pacific Gastrointestinal Market By Region, From 2016-2021 ( USD Billion )
  20. Asia-Pacific Genitourinary Market By Region, From 2016-2021 ( USD Billion )
  21. Asia-Pacific Infections Market By Region, From 2016-2021 ( USD Billion )
  22. Asia-Pacific Mental disorders Market By Region, From 2016-2021 ( USD Billion )
  23. Asia-Pacific Metabolic Market By Region, From 2016-2021 ( USD Billion )
  24. Asia-Pacific Musculoskeletal Market By Region, From 2016-2021 ( USD Billion )
  25. Asia-Pacific Nose Market By Region, From 2016-2021 ( USD Billion )
  26. Asia-Pacific Ophthalmology Market By Region, From 2016-2021 ( USD Billion )
  27. Japan Clinical Trial Market By Phase, From 2016-2021 ( USD Billion )
  28. Japan Clinical Trial Market By Design, From 2016-2021 ( USD Billion )
  29. Japan Clinical Trial Market By Indications, From 2016-2021 ( USD Billion )
  30. China Clinical Trial Market By Phase, From 2016-2021 ( USD Billion )
  31. China Clinical Trial Market By Design, From 2016-2021 ( USD Billion )
  32. China Clinical Trial Market By Indications, From 2016-2021 ( USD Billion )
  33. India Clinical Trial Market By Phase, From 2016-2021 ( USD Billion )
  34. India Clinical Trial Market By Design, From 2016-2021 ( USD Billion )
  35. India Clinical Trial Market By Indications, From 2016-2021 ( USD Billion )
  36. Australia Clinical Trial Market By Phase, From 2016-2021 ( USD Billion )
  37. Australia Clinical Trial Market By Design, From 2016-2021 ( USD Billion )
  38. Australia Clinical Trial Market By Indications, From 2016-2021 ( USD Billion )
  39. South Korea Clinical Trial Market By Phase, From 2016-2021 ( USD Billion )
  40. South Korea Clinical Trial Market By Design, From 2016-2021 ( USD Billion )
  41. South Korea Clinical Trial Market By Indications, From 2016-2021 ( USD Billion )
Middle East And Africa Radioimmunoassay Market By Type (Reagents And Kits Market, Analyzers Market), By End-User (Hospital, Pharmaceutical Industry And CRO, Academics And Clinical Diagnostic Laboratories), By Applic...
Latin America Radioimmunoassay Market By Type (Reagents And Kits Market, Analyzers Market), By End-User (Hospital, Pharmaceutical Industry And CRO, Academics And Clinical Diagnostic Laboratories), By Application (Re...
Asia Pacific Radioimmunoassay Market By Type (Reagents And Kits Market, Analyzers Market), By End-User (Hospital, Pharmaceutical Industry And CRO, Academics And Clinical Diagnostic Laboratories), By Application (Res...
Europe Radioimmunoassay Market By Type (Reagents And Kits Market, Analyzers Market), By End-User (Hospital, Pharmaceutical Industry And CRO, Academics And Clinical Diagnostic Laboratories), By Application (Research ...
North America Radioimmunoassay Market By Type (Reagents And Kits Market, Analyzers Market), By End-User (Hospital, Pharmaceutical Industry And CRO, Academics And Clinical Diagnostic Laboratories), By Application (Re...
Radioimmunoassay Market By Type (Reagents And Kits Market, Analysers Market), By End-User (Hospital, Pharmaceutical Industry And CRO, Academics And Clinical Diagnostic Laboratories), By Application (Research And Cli...
Middle East And Africa Nerve Repair And Regeneration Market By Product (Internal Neurostimulation Devices Such As Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, G...
Latin America Nerve Repair And Regeneration Market By Product (Internal Neurostimulation Devices Such As Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric El...
Asia Pacific Nerve Repair And Regeneration Market By Product (Internal Neurostimulation Devices Such As Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Ele...
Europe Nerve Repair And Regeneration Market By Product (Internal Neurostimulation Devices Such As Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrica...
North America Nerve Repair And Regeneration Market By Product (Internal Neurostimulation Devices Such As Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric El...
Nerve Repair And Regeneration Market By Product (Internal Neurostimulation Devices Such As Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimu...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.